Search

Your search keyword '"Zanamivir pharmacokinetics"' showing total 33 results

Search Constraints

Start Over You searched for: Descriptor "Zanamivir pharmacokinetics" Remove constraint Descriptor: "Zanamivir pharmacokinetics"
33 results on '"Zanamivir pharmacokinetics"'

Search Results

1. Population Pharmacokinetic/Pharmacodynamic Analysis of Intravenous Zanamivir in Healthy Adults and Hospitalized Adult and Pediatric Subjects With Influenza.

2. Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives.

3. Intrapulmonary Pharmacokinetics of Laninamivir, a Neuraminidase Inhibitor, after a Single Nebulized Administration of Laninamivir Octanoate in Healthy Japanese Subjects.

4. Preparation, characterization and pulmonary pharmacokinetics of a new inhalable zanamivir dry powder.

5. Computational assay of Zanamivir binding affinity with original and mutant influenza neuraminidase 9 using molecular docking.

6. Zanamivir Amidoxime- and N-Hydroxyguanidine-Based Prodrug Approaches to Tackle Poor Oral Bioavailability.

7. Optimizing antiviral therapy for influenza: understanding the evidence.

8. Zanamivir oral delivery: possibilities revisited.

9. Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study.

10. Pharmacokinetics of zanamivir following intravenous administration to subjects with and without renal impairment.

11. Effect of intravenous zanamivir on cardiac repolarization.

12. The pharmacokinetic and safety profiles of zanamivir after single and repeat intravenous administration in healthy Japanese males.

13. Permeability enhancers dramatically increase zanamivir absolute bioavailability in rats: implications for an orally bioavailable influenza treatment.

14. Structure-based design and synthesis of C-1- and C-4-modified analogs of zanamivir as neuraminidase inhibitors.

15. Population pharmacokinetics of laninamivir and its prodrug laninamivir octanoate in healthy subjects and in adult and pediatric patients with influenza virus infection.

16. Safety, tolerability and pharmacokinetics of orally inhaled zanamivir: a randomized study comparing Rotacap/Rotahaler and Rotadisk/Diskhaler in healthy adults.

17. Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.

18. A chemically programmed antibody is a long-lasting and potent inhibitor of influenza neuraminidase.

19. Synthesis of C-4-modified zanamivir analogs as neuraminidase inhibitors and their anti-AIV activities.

20. Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteers.

21. High and continuous exposure of laninamivir, an anti-influenza drug, may work suppressively to generate low-susceptibility mutants in animals.

22. Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach.

23. Zanamivir pharmacokinetics and pulmonary penetration into epithelial lining fluid following intravenous or oral inhaled administration to healthy adult subjects.

24. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.

25. An open-label crossover study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy Thai adults.

26. Characterization and in vitro evaluation of intestinal absorption of liposomes encapsulating zanamivir.

27. Assessment of the effects of renal impairment on the pharmacokinetic profile of laninamivir, a novel neuraminidase inhibitor, after a single inhaled dose of its Prodrug, CS-8958.

28. Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers.

29. Enabling the intestinal absorption of highly polar antiviral agents: ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir.

30. Pharmacokinetics and disposition of CS-8958, a long-acting prodrug of the novel neuraminidase inhibitor laninamivir in rats.

31. CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract.

32. [Neuraminidase inhibitors and risk of H5N1 influenza].

33. Pharmacokinetics and dosage adjustment of oseltamivir and zanamivir in patients with renal failure.

Catalog

Books, media, physical & digital resources